Amwell reports Q3 revenue of $56.3 million and net loss of $31.9 million

Reuters
11/05
Amwell reports Q3 revenue of $56.3 million and net loss of $31.9 million

American Well Corporation reported third quarter 2025 subscription revenue of $30.9 million and Amwell Medical Group visit revenue of $21.2 million. The company achieved a gross margin of 52.4%. Net loss was $31.9 million, compared to a net loss of $19.5 million in the previous quarter. Adjusted EBITDA was negative $12.7 million, compared to negative $4.7 million in the second quarter. Total visits reached 1.1 million. For full-year 2025, Amwell updated its revenue guidance to a range of $245 million to $248 million and narrowed its Adjusted EBITDA guidance to negative $45 million to negative $42 million. The company expects Amwell Medical Group visits between 1.3 million and 1.35 million. For the fourth quarter, revenue is expected to be between $51 million and $54 million, with Adjusted EBITDA between negative $15 million and negative $12 million. Amwell reiterated its objective to achieve positive cash flow from operations in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. American Well Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-264710), on November 04, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10